Table 2.

YAP-related resistance to targeted therapy in NSCLC.

YAP Alternation	Primary NSCLC Mutation	Resistance to Target Therapy (Primary/Secondary)	Targeted Therapy Resistance	Type of Study	Reference
YAP overexpression	EGFR mutation Exon 19 deletion/L858R+T790M	Primary/secondary	Erlotinib	Preclinical study	[71]
YAP overexpression	EGFR mutation L858R/exon 19 deletion/T790M	Primary/secondary	Erlotinib, Gefitinib, Afatinib, Osimertinib	Preclinical study and clinical analysis	[94]
YAP overexpression	L858R/exon 19 deletion /G719X/L861Q	Primary	Erlotinib, Gefitinib, Afatinib, Icotinib	Preclinical study and clinical analysis	[97]
YAP overexpression	EGFR mutation L858R/exon 19 deletion/T790M	Secondary	Osimertinib, Trametinib	Preclinical study	[98]
YAP overexpression	ALK fusion EML4-ALK fusion/	Secondary	Crizotinib, Ceritinib	Preclinical study	[96]
YAP overexpression	BRAF V600E, K-ras	Primary	Vermurafenib, Trametinib	Preclinical study	[89]